Clinical Trials Directory

Trials / Completed

CompletedNCT02389374

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
181 (actual)
Sponsor
Menzies School of Health Research · Academic / Other
Sex
All
Age
12 Months
Healthy volunteers
Not accepted

Summary

This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.

Detailed description

The national guidelines for the treatment of uncomplicated malaria in Bangladesh currently recommend a standard dose of artemether-lumefantrine followed by a single dose of primaquine for P. falciparum malaria and a three day course of chloroquine followed by 14 days of primaquine for vivax malaria.Currently the national treatment guidelines do not include any testing for G6PD deficiency before treatment with primaquine. In order to guarantee safe and efficacious treatment for all patients diagnosed with uncomplicated malaria in Bangladesh, it is essential to monitor the effectiveness and safety of the recommended treatment guidelines. This trial therefore evaluates the local efficacy and safety of the current first line treatment and assesses the G6PD status of the enrolled patients. Patients with uncomplicated malaria attending the health care center, who meet the study inclusion criteria will be enrolled, treated on site and followed up for 28 days. The follow-up will consist of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations. The study will provide efficacy data for both artemether-lumefantrine and chloroquine and will generate data on G6PD status in the region, which will provide vital information for policy makers in regards to the wider roll out of primaquine for the radical cure of vivax malaria.

Conditions

Interventions

TypeNameDescription
DRUGchloroquinestandard dose
DRUGArtemether-lumefantrine combinationstandard dose
DRUGPrimaquinesingle dose
DRUGPrimaquine14 days

Timeline

Start date
2014-08-01
Primary completion
2015-03-01
Completion
2015-03-01
First posted
2015-03-17
Last updated
2024-03-13
Results posted
2017-08-18

Source: ClinicalTrials.gov record NCT02389374. Inclusion in this directory is not an endorsement.